Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide - Wikidata - awgldk - TriplyDB

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

http://www.wikidata.org/entity/Q24796110

about

Immunologic aspect of ovarian cancer and p53 as tumor antigen.Inhibition of regulated cell death by cell-penetrating peptides Applications and Challenges for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos Functional characterisation of the WW minimal domain for delivering therapeutic proteins by adenovirus dodecahedron The genetics of the p53 pathway, apoptosis and cancer therapy.Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo The use of therapeutic peptides to target and to kill cancer cells.Peptide aptamers: recent developments for cancer therapy.Targeting p53 for Novel Anticancer Therapy.Inhibition of highly pathogenic avian influenza (HPAI) virus by a peptide derived from vFLIP through its direct destabilization of viruses.Design of embedded chimeric peptide nucleic acids that efficiently enter and accurately reactivate gene expression in vivo Evidence for a novel mechanism of the PAK1 interaction with the Rho-GTPases Cdc42 and Rac.Theranostic protein targeting ErbB2 for bioluminescence imaging and therapy for cancer.Characterisation of cell-penetrating peptide-mediated peptide delivery Effects of the properties of short peptides conjugated with cell-penetrating peptides on their internalization into cells Predicting the effect of transcription therapy in hematologic malignancies.Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo.Transactivating transcriptional activator-mediated drug delivery.Inhibiting bladder tumor growth with a cell penetrating R11 peptide derived from the p53 C-terminus.Influence of protein transduction domains on intracellular delivery of macromolecules.Reactivation of mutant p53: molecular mechanisms and therapeutic potential.Therapeutic targets in the ARF tumor suppressor pathway.Identification and functional characterization of the human glutathione S-transferase P1 gene as a novel transcriptional target of the p53 tumor suppressor gene.A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics.Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor Inhibition of ovarian cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally responsive polypeptide carrier.Transport molecules using reverse sequence HIV-Tat polypeptides: not just any old Tat? (WO200808225).Cell-penetrating peptides: achievements and challenges in application for cancer treatment.Therapeutic potential of cell-penetrating peptides.Bioportides: bioactive cell-penetrating peptides that modulate cellular dynamics.Cell-penetrating peptides: A tool for effective delivery in gene-targeted therapies.Cell penetration: scope and limitations by the application of cell-penetrating peptides.Peptide-mediated delivery: an overview of pathways for efficient internalization.Pharmacological reactivation of p53 as a strategy to treat cancer.Cationic PTD/CPP-mediated macromolecular delivery: charging into the cell.Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.Building Cell Selectivity into CPP-Mediated Strategies.

P2860

Q24814703-B740B0A8-47C0-4117-85BF-CFABFEA94F55 Q26751423-1412D0DD-EC27-4E3C-BB5A-684638E4B7B8 Q26769800-1E35EBEA-EBB7-4554-A998-DC09B3A58267 Q27318180-C48775B5-0684-4E3D-A736-2A5988A3E33B Q27863460-F91B6749-D42D-447E-B235-F5F9A06A53C8 Q28077156-B691C169-25E2-48D9-86CD-8151E08B7C68 Q28486075-89DC29EF-DBDC-43D9-AD8E-61C6539AF2E6 Q28507164-42C84C24-B5F0-475D-9B68-CFDB2A9678EA Q30418414-9D41BA73-915A-4917-AA94-C59FF41C2BC7 Q33216999-2F977A1B-89B9-40C3-9DC5-E692F47B8F26 Q33655329-599861D3-EAC6-4333-B694-E5480CE8C895 Q33884759-EFB3E3B3-2660-4864-B5E8-ED1589D366F8 Q34165634-4F9D655C-5298-411A-872C-8D7329520372 Q34926820-376F50C7-854B-43C5-8818-4DAE29A4B820 Q34999521-EE65AECD-38C4-47EC-8105-BA518434BCBA Q35049077-A326BB7A-3EDA-457A-8F40-347D78F22AC2 Q35740804-D3D8991D-51F2-4873-98CF-874C75403CF5 Q36109663-69A56DD8-9056-47BC-B037-C0C5280DBB2A Q36316659-3F46BFCB-5B72-4A98-84E7-13C3DB2071E3 Q36409033-E3EE59A6-E3AF-4662-AE3A-BDFA34CE37BC Q36545877-2C3A4042-16F6-4551-B859-27AE434F3AC9 Q36640321-84937349-BE36-4102-8687-F2BBA26ABBDE Q36777373-11B2E698-7130-40CE-B887-5517FBA0E02B Q36879301-1E9E7565-7A27-4C8D-96C0-8913827E3441 Q36943260-5CC516D6-F472-4D88-9C39-CF855848E8C7 Q37157963-A74974D8-C26E-44E3-8672-FFF2306B60DB Q37230918-3E9B5EE2-AD68-4231-BB30-724958804090 Q37259663-7AA69806-562A-40E7-82FA-620676B09133 Q37480921-83FC99AE-963B-4F26-8374-5B6F4C6FAE2F Q37530890-D0666DA6-CBC4-4F8A-98BA-ECAFAA04CBAC Q37594526-DE92CDE8-3856-4F8D-A978-31424339F27B Q38104407-122AA7C8-775C-42DB-992F-48E330A0C06B Q38120721-7321D1EC-42DA-46C1-A29A-FA14B2999C76 Q38198590-D588C0FC-EF60-445F-BE50-A647A9B8F5A9 Q38238902-C10B8D39-D348-4485-9F2C-FF9F08329D3A Q38285852-8F2A507C-42B8-48E1-8A80-F236A504A841 Q38286198-46F29876-8479-4701-976E-69AEB77CD9ED Q38494545-2AE300B6-E3DB-40AD-BBD6-4226ACF75107 Q38710470-296ACD48-F068-462A-8961-833939A3D704 Q38974301-A4567168-CC8B-40D8-8790-53FC93E6A463

P2860

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

http://www.wikidata.org/entity/Q24796110

description

2004 nî lūn-bûn

@nan

2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

@ast

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

@en

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

@nl

type

label

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

@ast

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

@en

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

@nl

prefLabel

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

@ast

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

@en

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

@nl

P1433

Q24796110-AEA8CF43-13B3-488D-B8DB-0FFF1430B225

P1476

Q24796110-A9726BDA-BFFF-4AC0-A415-21E427BB0640

P2093

Q24796110-0006E16B-3A67-481F-AD19-6FCE003455F1

Q24796110-2EEC94F0-2E18-44BD-B464-8E515755B2B7

Q24796110-3A04DE5B-17C0-48FA-8009-57AD24BD1C24

Q24796110-4ED5146F-28B5-4DB6-A70F-E0F82F14CA71

P2860

Q24796110-08FF5E4F-4F15-4BFD-AC80-D2377E1A7F3B

Q24796110-0D5553BB-D4D3-491D-8E78-FE6295FB8A4B

Q24796110-0EC2B0BB-1440-4658-BD52-B8C045C9FE82

Q24796110-120833F3-5609-4A4E-8A7E-E021FC35D833

Q24796110-170184AC-6E97-4513-B178-5548D4051AB2

Q24796110-1C29C66C-70CD-462B-B732-2D88CD95CA80

Q24796110-1DD90A3C-4F6C-4534-A613-1C162C426E34

Q24796110-1F3286A9-AE74-454A-A3C3-D47E11B8A26C

Q24796110-2874F4A4-3AE1-4037-8E9C-1B820140D806

Q24796110-290EF8D3-48E6-4DF9-8254-25B142398405

P304

Q24796110-85FB3A0C-E450-4DBE-8AC4-2B5E0A0B77C3

P31

Q24796110-3931B678-0328-40F9-8B1E-270018970D19

P3181

Q24796110-37BF6893-288E-407D-BB5B-0C028DB8DB7E

P356

Q24796110-4C40D5C6-BB80-429D-9F79-AEA2DB2A64C1

P407

Q24796110-DFADA0A4-499B-4AF3-B618-6F6150195512

P433

Q24796110-6FF4714A-C9D3-420F-8E25-E54E24BF7AA2

P478

Q24796110-B57EAE03-3407-42C8-8CF7-009037469797

P577

Q24796110-A5FBAF02-27D1-4BC2-A76D-DAB5F0329182

P5875

Q24796110-8172CD53-3DE0-4312-86D5-792561996CE5

P698

Q24796110-F4F481DB-27F5-45CB-A928-80D3DF2A250E

P932

Q24796110-FDBA9C49-A8CB-471F-8AF3-B02834F5C0E0

P3181

P356

JOURNAL.PBIO.0020036

P1433

P1476

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

@en

P2093

Bryan R Meade

http://www.w3.org/2001/XMLSchema#string

Cheryl C Saenz

http://www.w3.org/2001/XMLSchema#string

Eric L Snyder

http://www.w3.org/2001/XMLSchema#string

Steven F Dowdy

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor suppressor genes

Live or let die: the cell's response to p53

Requirement for p53 and p21 to sustain G2 arrest after DNA damage

The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited

In vivo protein transduction: delivery of a biologically active protein into the mouse

Post-translational modifications and activation of p53 by genotoxic stresses

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

Advances in ovarian cancer chemotherapy.

Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation.

Cancer gene therapy: fringe or cutting edge?

P304

E36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2474620

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PBIO.0020036

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2004-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6622543

http://www.w3.org/2001/XMLSchema#string

P698

14966535

http://www.w3.org/2001/XMLSchema#string

P932

340944

http://www.w3.org/2001/XMLSchema#string